The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

Amlenetug is tailored to attach to all major extracellular α-synuclein forms. The human monoclonal antibody aims to prevent ...

Lundbeck’ amlenetug receives Japanese orphan drug designation for treatment of multiple system atrophy: Denmark Tuesday, March 11, 2025, 11:00 Hrs [IST] H. Lundbeck A/S (Lundbec ...

The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug ...

Alvogen Inc.’s proposed generic version of Abilify Maintena infringes six patents for the schizophrenia treatment that an Otsuka Holdings Co. unit exclusively licenses to H. Lundbeck A/S, a federal ...

The FDA has granted Fast Track Designation to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). Lundbeck has recently initiated ...

Lundbeck is developing the drug under a licencing agreement with Genmab. Credit: Copyright© 2025 H. Lundbeck A/S. Lundbeck has received the US Food and Drug ...

The FDA has granted Fast Track Designation to Lundbeck’s investigational drug, amlenetug, a potential new treatment option targeting Multiple System Atrophy (MSA). This designation is based on the ...

International pharmaceutical company Lundbeck deployed a secret agent to the Gaza Strip in addition to hiring a missing-persons expert when campaigning for the release of its employee, former ...